This article is more than 5 years old. Information may no longer be current.
VIDEO: Data on smoking cessation, diabetes therapies promising for CVD prevention
Click Here to Manage Email Alerts
ORLANDO, Fla. — Pamela B. Morris, MD, associate professor of medicine at the Medical University of South Carolina and chair of the American College of Cardiology’s Prevention of Cardiovascular Disease Leadership Council, discusses new research “making a significant impact” in primary and secondary CVD prevention.
Morris reviews “very important” data from the EVITA study looking at the effect of the smoking-cessation agent varenicline (Chantix, Pfizer) in patients hospitalized for ACS that “tells us … we can achieve successful tobacco cessation, at least out to approximately 12 weeks postdischarge.”
She details results from an investigation that explored potential approaches to improve treatment adherence and LDL cholesterol-lowering among outpatients, suggesting “we have much to learn … and we need to think about whether or not financial incentives are really a cost-effective approach to improving care.”
Morris also touches on the EMPA-REG Outcome study, which showed “dramatic benefits” in CV death and hospitalization for HF in high-risk patients with diabetes treated with empagliflozin (Jardiance, Boehringer Ingelheim).